Tariffs, Translucence & Tesla: A 30-Minute Tour of Markets in Flux (e2524)

SHOWNOTESThis week Mike, Jason, and Hunt sprint through oil, gas, tariffs, chips, tech launches, AI financing drama, and the brewing revolt against pharmacy-benefit managers—wrapping with Harrow’s latest capital-allocation coup.[00:00] Intro [00:01] Exhibit C – Oil Oversupply & the Iran Stalemate (Exhibit C)Hunt explains why global crude stays firm near $65–66 despite clear oversupply, tracing it to dead-locked U.S.–Iran negotiations over centrifuges.[00:02] Exhibit B – Natural Gas Holds the Line (Exhibit B)Production hovers around 106 Bcf/d; flat U.S. power demand is offset by LNG exports and cold-weather consumption, keeping prices around $4.[00:03] Exhibit A – Tariffs & U.S. Fiscal Math (Exhibit A)Tariff receipts could hit $700 B if it reaches $60 B per month. Jason notes China-related levies may settle near 35 % (ex-fentanyl).[00:04] Rare-Earth Magnets vs. NVIDIA Chips: Trade-Deal Leverage (p.1)China throttles drone-part exports and magnets; the U.S. counters with chip restrictions—highlighting mutual dependencies and a possible “chips-for-magnets” swap.[00:07] CPI Calm Despite Tariff Talk (Exhibit A)May inflation data shows little price pressure so far, challenging economists’ warnings of tariff-driven CPI spikes.[00:07] Chip History – From 386 to the WINTEL Juggernaut (p.3)Mike and Jason revisit Intel’s pivot to CPUs, the rise of the 386, Microsoft’s DOS/Windows partnership, and the CISC vs. RISC debate that shaped desktop dominance.[00:14] Apple WWDC: Liquid-Glass UX & the Missing AI Play (p.1)Jason critiques Apple’s “liquid glass” interface—translucent icons that hint at an AR future—while lamenting Cupertino’s AI lag despite iron-clad customer lock-in.[00:18] xAI’s $5 B Debt Deal Stumbles (p.1)Morgan Stanley shelves a 12 % syndicated loan after Elon’s tweet-storm; Hunt wonders if weak X/Twitter revenue can support the spend.[00:19] Could Tesla Scoop Up xAI? (p.1)Jason weighs the pros and cons of rolling xAI into Tesla—synergies with FSD and humanoid robots versus dilution and distraction.[00:22] UnitedHealth, PBMs & the Rot in U.S. Healthcare (p.19)The crew argues that dismantling pharmacy-benefit managers is step #1 to break insurers’ “raise-premiums-faster-than-costs” model, potentially shrinking UNH’s growth engine.[00:27] Harrow Licenses BYQLOVI™ for Peanuts (p.20)Harrow (HROW) nabs U.S. rights to a nanoparticle steroid eyedrop for only $500 K—an ideal plug-in for its ophthalmology sales force and a textbook capital-allocation win.[00:29] Outro This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com